World Multiple Sclerosis Day

Today 30 May , is celebrated the world day of Multiple Sclerosis. Multiple Sclerosis (Multiple Sclerosis) is a chronic demylinizing disease of the Central Nervous System (CNS), which affects the brain and spinal cord, causing physical, emotional and cognitive disorders. It typically affects young adults with a higher incidence of cases in women (the average age of the first symptom is 29) whose origin is unknown. The EM is known more than 140 years ago, in 1868. The first descriptions were made in 1835 by Cruveilhier and in 1838 by Carswell, but it was in 1868 by Dr. Jean Marie Charcot who offered the first description of the clinical and evolutionary aspects of the disease, making the correlation between clinical data and autopsies. La. multiple sclerosis affects 50,000 people in Spain 700,000 people in Europe and 2.5 million people worldwide, according to data from the Society Spanish of Neurology (SEN). It is usually considered a single disease, but its evolution and symptoms vary according to the person, which is why people with multiple sclerosis may suffer very different symptoms, so it is known as a person. the disease of the thousand faces . In addition, the speed or slowness with which the disease progresses and the possible relapses can be unpredictable which makes the adaptation to live with EM more complicated. In our Clinical Trials Unit we have several clinical trials in which you can participate if you are interested. REMODEL: Randomized, double-blind, double- masked study and parallel groups comparing the efficacy and safety of remibrutinib against teriflunomide in participants with recurrent multiple sclerosis, followed by an open extension of treatment with remibrutinib. GEMINI2: Phase 3, randomized, double-blind study to evaluate the efficacy and safety of treatment with SAR442168 versus teriflunomide (Aubagio®) in patients with recurrent multiple sclerosis. PERSEUS: Phase 3, randomized, double-blind study to evaluate the efficacy and safety of treatment with SAR442168 versus placebo in patients with progressive primary multiple sclerosis. STHENOS: Open, randomized study, with blind, multicenter, parallel arms evaluator, with active comparison to evaluate the effectiveness and tolerability of Ofatumumab 20 mg s.c. administered monthly vs. First-line TME to doctor's choice in the treatment of patients with recent diagnosis of Multiple Sclerosis (Multiple Recurrent Sclerosis). HERCULES: Phase 3, randomized, double-blind study to evaluate the efficacy and safety of treatment with SAR442168 versus placebo in patients with non-recurrent progressive secondary multiple sclerosis. FENTREPID: Phase III multicenter, randomized, double-blind, with double masking and parallel groups to assess the effectiveness and safety of Fenebrutinib compared to Ocrelizumab in adult patients with Progressive Primary Multiple Sclerosis. OPERETTA2 : Phase III, multicenter, randomized, double-blind, and dual simulation study to assess the safety and effectiveness of ocrelizumab compared to fingolimod in children and adolescents with multiple sclerosis multiple sender-recurrent sclerosis. You can contact us via email unitensayosneurologiamalaga@gmail.com or through the form doing click here